National Comprehensive Cancer Network Guideline Updates From the 15th Annual Congress

Credits: 1.0 contact hours (0.10 CEUs)

Author: Anthony Elias, MD, Professor of Medicine, Medical Director, Breast Cancer and Sarcoma Programs, University of Colorado Cancer Center

Author Disclosure: Anthony Elias, MD, discloses that he has received grants for clinical trials from Pfizer and Roche.

Planning Committee Disclosures: Independent medical writer William Yarnall, RPh, CCP, and the staff of Pharmacy Times Office of Continuing Professional Education and The American Journal of Pharmacy Benefits have nothing to disclose relative to this activity.

Educational Objectives

After completing this activity, participants should be able to:

• List some of the major National Comprehensive Cancer Network (NCCN) practice guideline revisions presented at the 15th Annual Congress
• Identify select NCCN guideline revisions that may impact the course of treatment in a given case
• Discuss the use of patient characteristics to determine therapeutic management in select NCCN guideline revisions

Target Audience: Pharmacy directors/administrators, clinical pharmacists practicing in managed care environments, and any other pharmacist practitioners involved in the care of patients diagnosed with cancer.